Friday, 22 January 2021

Boehringer Ingelheim appoints Vani Manja as Country Managing Director for India 

11 January 2021 | News

Manja was formerly the Global Head of Boehringer Ingelheim’s Go-To-Market and Business Steering organisation, based in the Company’s headquarters in Germany

Boehringer Ingelheim has announced that Vani Manja is appointed Country Managing Director for India, effective January 1, 2021. In this role, she will assume responsibility for the Company’s businesses in India, Bangladesh, Nepal and Sri Lanka. Manja will also join the Board of the Company.

Announcing Manja’s appointment, Thorsten Poehl, Head, Emerging Markets, Boehringer Ingelheim said, “Vani is a proven and respected leader who lives our Company values and has a strong track record of leading complex transformations and delivering results. With her unwavering commitment to patients, customers and employees, I am confident that Vani will lead the India business to build patient-friendly access and benefit models in the years to come.

Manja was formerly the Global Head of Boehringer Ingelheim’s Go-To-Market and Business Steering organisation, based in the Company’s headquarters in Germany. She joined Boehringer Ingelheim in the US in 2011, working across Strategy & Operations, Marketing and Sales leadership roles before moving to Ingelheim in 2016 as Regional Business Manager for Japan. Her global experience in healthcare spans nearly two decades across McKinsey & Company, Becton Dickinson and Boehringer Ingelheim, and is characterised by strong global mobility and cross-functional leadership assignments across healthcare and management consulting.

Manja holds an MBA and MA in International Studies from the Wharton School at the University of Pennsylvania in Philadelphia, and a Bachelor’s degree with Honours in Chemistry from Delhi University.

Manja said, “I look forward to working with our customers, partners and leaders in healthcare to improve the lives of patients through innovative therapies, after all the years of remotely following the huge strides India has taken towards developing healthcare.”

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account






Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls